Explore immunotherapy discoveries, treatment approvals and milestones.
See Our Breakthroughs
Working to make a difference in the lives of all affected by cancer.
Learn About Our Work
Learn more about this revolutionary cancer treatment.
Understand the Basics
Find clinical trials that match your diagnosis, stage and treatment history.
Meet the CRI scientists committed to the development of immunotherapy.
Days 4 and 5 at ASCO17 showed off the overall scope of immunotherapy’s efforts to provide clinical benefits to patients. Many next-generation immune-based treatments were discussed, including some of which may represent the future standard of care for some cancers. Below are some of the most important findings revealed during the final two days of the conference:
Multiple Tumor Types:
Watch our story about Carol, one of the patients treated on this trial.
Head and Neck Cancer:
ASCO17: Day 3 Immunotherapy Highlights
Read Previous Article
ASCO17 Recap: 7 Takeaways from the World’s Premier Clinical Cancer Conference
Read Next Article
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, 4th Floor | New York, NY 10006-3111
(800) 992-2623(212) 832-9376Staff Directory
FDA approves new immunotherapy--Yescarta (axicabtagene ciloleucel)--for adult patients with relapsed or refractory non-Hodgkin large B cell lymphoma.
CRI among 12 top-rated cancer charities within a subset of organizations doing good work in breast cancer as well as other forms of cancer.